Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to NSCLC
Related studies linked through entity extraction aliases.
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
- Status
- WITHDRAWN
- Phase
- PHASE3
Conmana Combined With Thalidomide to Treat NSCLC
- Status
- UNKNOWN
- Phase
- PHASE4
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
- Status
- COMPLETED
- Phase
- PHASE3
A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Study of Endostar Subcutaneous Injection in NSCLC
- Status
- UNKNOWN
- Phase
- PHASE1
Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
- Status
- TERMINATED
- Phase
- PHASE1
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients
- Status
- TERMINATED
- Phase
- N/A
Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia
- Status
- COMPLETED
- Phase
- NA
Echocardiography for RILI Prediction
- Status
- TERMINATED
- Phase
- N/A
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1
Study of the CD40 Agonistic Monoclonal Antibody APX005M
- Status
- COMPLETED
- Phase
- PHASE1
Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
- Status
- TERMINATED
- Phase
- PHASE2
Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients
- Status
- TERMINATED
- Phase
- PHASE2
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
- Status
- UNKNOWN
- Phase
- PHASE4